Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 8Withdrawn 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma 2Hematologic Neoplasms 2Subcutaneous panniculitis-like T-cell lymphoma 1Sezary Syndrome 1Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Infectious Mononucleosis 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Vorinostat 2Stem Cell Transplantation 2Rituximab 2Gemcitabine 2Busulfan 2Brentuximab Vedotin 2romidepsin 1pembrolizumab 1molibresib 1entinostat 1copanlisib 1belinostat 1Tacrolimus 1Pyridoxine 1Panobinostat 1Mycophenolic Acid 1Melphalan 1Health Resources 1Granulocyte Colony-Stimulating Factor 1Glutamine 1Filgrastim 1Fibroblast Growth Factor 7 1Dexamethasone 1Cyclophosphamide 1Cryotherapy 1Clofarabine 1Calcium Dobesilate 1CT-P10 1Bortezomib 1BI 6727 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, T-Cell × Brentuximab Vedotin × Clear all
NCT04795869 2023-10-10

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Northwestern University

Phase 2 Withdrawn
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT04334174 2023-02-03

BRENTICON-T

University of Kansas Medical Center

Phase 2 Withdrawn
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡